Loading clinical trials...

The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma

NCT06863441•Ruijin Hospital

View on ClinicalTrials.gov

Summary

The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.

Detailed Description

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age \> 18 years, regardless of gender.
•2. Histopathologically confirmed diagnosis of T-NK cell lymphoma.
•3. Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy.
•4. Availability of complete clinicopathological and follow-up data.
•5. Signed and dated informed consent form.

Exclusion Criteria

•1. Patients who have previously received anti-tumor therapy.
•2. Patients with a history of other malignancies.
•3. Incomplete clinical information or imaging data.
•4. Concurrent other malignant tumors.
•5. Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction.
•6. Poor compliance.

Locations (1)

Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School, Shanghai

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

March 1, 2025

Primary Completion Date

December 31, 2029

Completion Date

December 31, 2029

Last Updated

March 7, 2025

Enrollment

ESTIMATED participants

Conditions

T-NK Cell Lymphoma

Contacts

Xinyu Zhang

CONTACT

15958022176 zhangxinyu76@126.com

The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study

NCT06747299

T-NK Cell Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions